Surface Cytotoxic T Lymphocyte–associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation by Darlington, Peter J. et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/05/1337/11 $5.00
Volume 195, Number 10, May 20, 2002 1337–1347
http://www.jem.org/cgi/doi/10.1084/jem.20011868
 
1337
 
Surface Cytotoxic T Lymphocyte–associated Antigen 4 
Partitions Within Lipid Rafts and Relocates to the 
Immunological Synapse under Conditions of Inhibition of T 
Cell Activation
 
Peter J. Darlington,
 
1
 
 Miren L. Baroja,
 
1
 
 Thu A. Chau,
 
1
 
 Eric Siu,
 
1
 
 Vincent Ling,
 
2 
 
Beatriz M. Carreno,
 
2
 
 and Joaquín Madrenas
 
1
 
1
 
The Biotherapeutics and Transplantation and Immunobiology Groups, The John P. Robarts Research Institute, and 
The Departments of Microbiology and Immunology, and Medicine, The University of Western Ontario, London, 
Ontario N6A 5K8, Canada 
 
2
 
Wyeth-Genetics Institute Incorporated, Cambridge, MA 02140
 
Abstract
 
T cell activation through the T cell receptor (TCR) involves partitioning of receptors into dis-
crete membrane compartments known as lipid rafts, and the formation of an immunological
synapse (IS) between the T cell and antigen-presenting cell (APC). Compartmentalization of
negative regulators of T cell activation such as cytotoxic T lymphocyte–associated antigen-4
(CTLA-4) is unknown. Recent crystal structures of B7-ligated CTLA-4 suggest that it may
form lattices within the IS which could explain the mechanism of action of this molecule.
Here, we show that after T cell stimulation, CTLA-4 coclusters with the TCR and the lipid
raft ganglioside GM1 within the IS. Using subcellular fractionation, we show that most lipid
raft-associated CTLA-4 is on the T cell surface. Such compartmentalization is dependent on
the cytoplasmic tail of CTLA-4 and can be forced with a glycosylphosphatidylinositol-anchor
in CTLA-4. The level of CTLA-4 within lipid rafts increases under conditions of APC-depen-
dent TCR–CTLA-4 coligation and T cell inactivation. However, raft localization, although
necessary for inhibition of T cell activation, is not sufficient for CTLA-4–mediated negative
signaling. These data demonstrate that CTLA-4 within lipid rafts migrates to the IS where it
can potentially form lattice structures and inhibit T cell activation.
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Introduction
 
An increasing body of evidence indicates that T cell activa-
tion involves lateral migration of many molecules associ-
ated with TCR-mediated signaling. When T cells are stim-
ulated with planar lipid bilayers or APCs possessing
antigenic peptide–MHC, a highly ordered macromolecular
interface termed immunological synapse (IS)
 
*
 
 forms be-
tween the T cell and the APC surface (1). The IS is com-
posed of a central core containing TCR/CD3, PKC
 
 
 
, lck,
fyn, and CD28, surrounded by a ring enriched for LFA-1
talin, and CD43 (2–5). The organization of such an inter-
face is determined in part by the intermembrane dimen-
sions of the synapse, which may exclude complexes that
encompass more than 15 nm (6). At a submicroscopic
level, formation of an IS correlates with clustering of gly-
colipid-enriched microdomains known as lipid rafts. These
domains move into the IS in response to CD3 and CD28
ligation (7). Lipid rafts are enriched with signaling mole-
cules critical for TCR-mediated signaling such as lck,
linker for activation of T cells (LAT), and PKC
 
 
 
 (8–10),
and their biological integrity is essential for proper TCR-
mediated signaling (8, 11).
In the context of the lipid raft/IS paradigm, the com-
partmentalization of negative regulators of T cell activa-
tion remains largely unexplored. Establishing this compart-
mentalization may provide insights into their mechanism
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of action as well as help us to understand the structural na-
ture of receptor-mediated T cell activation. To address this
issue, we looked at one of the main negative regulators of
T cell activation, CTL-associated antigen 4 (CTLA-4).
CTLA-4 is an activation-induced, type 1 transmembrane
protein expressed by T cells (12). Upon coligation with
the TCR, CTLA-4 blocks IL-2 gene transcription and
prevents the entry of T cells into the growth phase beyond
G1/G0 leading to inhibition of T cell proliferation (13,
14). Such an inhibitory effect on T cell activation is illus-
trated by the unregulated lymphoproliferation and multi-
organ autoimmunity observed in CTLA-4–deficient mice
(15–18).
CTLA-4 can inhibit T cell responses by two different
mechanisms (for a review, see reference 19). One mecha-
nism involves antagonism of B7-CD28–mediated costimu-
latory signals by CTLA-4 (20), which occurs because
CTLA-4 has a much higher affinity for B7 than does CD28
(21, 22). This mechanism is only dependent on the extra-
cellular domain of CTLA-4 and is operational in a manner
directly proportional to the level of surface expression (20).
A second mechanism by which CTLA-4 can inactivate T
cells involves the delivery of a negative signal (23–26). In
contrast to CTLA-4–mediated sequestration of B7, nega-
tive signaling by CTLA-4 requires the cytoplasmic tail of
CTLA-4 and is operational at low levels of surface expres-
sion (20). However, the precise molecular nature of
CTLA-4–mediated negative signaling remains controver-
sial (23, 24, 26–28).
Recently, several crystal structures of CTLA-4 and the
CTLA-4–B7 complex have been reported (29–32).
These structures indicate that the predicted intermem-
brane distance of the B7–CTLA-4 complex may be in
the range of the MHC–TCR interaction (
 
 
 
130–150 Å)
and would thus fit within the central core of the IS.
More importantly, the topology of CTLA-4 dimers li-
gated with B7 dimers suggest that CTLA-4 may form
high order oligomers at the IS. If such a lattice forms, it
may lead to disruption of the structure and/or function
of the synapse. To test this hypothesis, we examined the
distribution of CTLA-4 on the T cell surface under con-
ditions of CTLA-4–mediated inhibition of T cell activa-
tion. We report that CTLA-4 colocalizes with TCR/
CD3 complex and the ganglioside GM1 within the IS
upon exposure to superantigen and APC. When lipid
rafts were analyzed in conditions of CTLA-4–mediated
inhibition, we found that although most CTLA-4 parti-
tioned in detergent soluble fractions, a detectable fraction
of the surface pool of CTLA-4 was within lipid rafts.
Moreover, CTLA-4 in lipid rafts was homodimeric and
its levels increased upon exposure to superantigen and
APCs. The partition of CTLA-4 within lipid rafts was
dependent on the cytoplasmic tail of CTLA-4. The pres-
ence of CTLA-4 in lipid rafts was necessary, but not suf-
ficient for T cell inhibition to occur since a glycosylphos-
phatidylinositol
 
 (
 
GPI)-anchored version of CTLA-4 was
targeted exclusively to lipid rafts but failed to deliver an
inhibitory signal.
 
Materials and Methods
 
Cell Lines and Transfectants.
 
The human leukemia T cell line
Jurkat, E6.1 was obtained from the American Type Culture Col-
lection, and maintained in RPMI with 10% FCS. Jurkat T cells
expressing doxycycline-inducible wild-type or tailless CTLA-4
molecules (that have the transmembrane but not the cytoplasmic
region of CTLA-4) have been described previously (24). New for
the studies reported here is the human GPI-anchored CTLA-4,
which is a fusion construct comprised of sequences corresponding
to a Kozak sequence and the extracellular region of human
CTLA4 (GenBank/EMBL/DDBJ accession no. AF414120)
fused by a spacer sequence to the sequence corresponding to the
carboxy-terminus of the glycosylphosphatidylinositol-linked iso-
form of CD58/LFA-3 (GenBank/EMBL/DDBJ accession no.
XM_040693, positions 548–792). Human CTLA-4-gpi was sub-
cloned into the doxycycline inducible vector pBIG2i at the XhoI
multiple cloning site. Transfection and subcloning was done as
described previously (24). CTLA-4 was induced by overnight in-
cubation with doxycycline (Sigma-Aldrich) at a concentration of
100 ng/ml for IL-2 production assays, or 5 
 
 
 
g/ml for biochemi-
cal experiments. The B lymphoblastoid cell line LG2, which ex-
presses high levels of HLA-DR1 and B7, was provided by Dr.
Eric Long (Molecular and Cellular Immunology Section, Labora-
tory of Immunogenetics, National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health, Rockville, MD) and
maintained in RPMI with 10% FCS.
 
Antibodies and Reagents.
 
The following antibodies were used
in this study: T cell functional assays were performed using beads
coated with monoclonal antibodies against human CD3
 
 
 
(UCHT-1; BD PharMingen), human CTLA-4 (anti-CTLA-4–
20A; Wyeth-Genetics Institute Inc.), or against HLA-class I
molecules (G46–2.6; BD PharMingen). A monoclonal anti-
body against human CD28 (CD28.2), FITC-labeled anti-CD3
(UCHT-1), and PE-labeled anti-CTLA-4 (BNI3) antibodies
were purchased from BD PharMingen. A mouse anti–human
ScFv CTLA-4 F
 
 
 
ab fragment was generated by recombinant
technology and provided by Genetics Institute. A FITC-labeled
antibody against pan-CD45 (HI30) and a FITC-labeled antibody
against CD43 (1G10) were purchased from BD PharMingen.
GM1 analysis was performed with FITC-cholera toxin B subunit
(Molecular Probes). CTLA-4 was immunoprecipitated with the
anti–human CTLA-4–24 monoclonal antibody, and immuno-
blotted with the anti-CTLA-4–11 monoclonal antibody, both
from Wyeth-Genetics Institute Inc. Appropriate isotype-matched
antibody controls were purchased from Southern Biotechnology
Associates, Inc. ERK-1/-2 were blotted using a rabbit antiserum
from StressGen Biotechnologies. Biotinylated molecules were
immunoprecipitated with an antibody against biotin from Jackson
Immunoresearch Laboratories.
 
Inhibition of IL-2 Production by CTLA-4.
 
To assay inhibition
of superantigen-mediated stimulation by CTLA-4, 0.5 
 
 
 
 10
 
6
 
transfectants were incubated for 48 h with 0.25 
 
 
 
 10
 
6
 
 LG2 plus 5
ng/ml staphylococcal enterotoxin E (SEE; Toxin Technology
Inc.), with or without 100 ng/ml doxycycline. To assay for inhi-
bition of IL-2 production by CTLA-4–mediated negative signal-
ing, Jurkat T cells (5 
 
 
 
 10
 
5
 
/group) were incubated with anti-
CD3 and anti-HLA-class I–coated beads or with anti-CD3 and
anti-CTLA-4–coated beads, in 24-well plates for 48 h in the
presence of soluble anti-CD28 monoclonal antibodies (20 
 
 
 
g/
ml), as described previously (20, 33). IL-2 in the supernatants was
analyzed by ELISA. For the blocking of CTLA-4–mediated inhi-
bition of IL-2 production, 0.5 
 
 
 
 10
 
6
 
 Jurkat T cells were preincu-
bated with 100 ng/ml of doxycycline and a total of 10 
 
 
 
g of anti- 
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CTLA-4 ScFv CTLA-4 F
 
 
 
ab fragment. After 30 min of preincu-
bation, antibody-coated beads plus soluble anti-CD28 antibody
or APCs and SEE were added to the samples.
 
Confocal Microscopy.
 
35-mm glass bottom microwell dishes,
(MatTek Corp.) were coated overnight with poly-L-lysine
(Sigma-Aldrich). T cells (1.0 
 
 
 
 10
 
6
 
) were incubated on the plates
for 30 min before adding LG2 cells that had been preincubated
with 100 ng/ml SEE for 30 min. Dishes were washed twice with
PBS plus 1% FCS, stained with PE-labeled anti-CTLA-4 (30
min on ice) followed by FITC-labeled anti-CD3 or FITC-labeled
cholera toxin B subunits. Image capture was done with a confo-
cal microscope (Carl Zeiss, Inc.) and analyzed with the LSM 510
software (Carl Zeiss, Inc.; Microsoft). Quantitation of CD3-
CTLA-4 colocalization at the putative immunological synapse
was performed on at least 100 T cell–APC doublets. Capping for
each molecule at the interface between the T cell and the APC
was scored when the staining was visible on 
 
 
 
50% of the T cell
surface.
 
Flow Cytometry.
 
Jurkat T cells (1.0 
 
 
 
 10
 
6
 
/group) were
washed twice with PBS and stained with FITC-labeled anti-
CD3, FITC-labeled anti-CD28, PE-labeled anti–CTLA-4, or
FITC-labeled anti-CD45 in ice for 30 min. Samples were then
washed twice in PBS and analyzed by flow cytometry (FAC-
Scan™ and CELLQuest™ software; BD PharMingen).
 
Lipid Raft Isolation and Biochemistry.
 
LG2 cells (0.5 
 
 
 
 10
 
6
 
/ml)
in 6-well plates were preincubated with 100 ng/ml of SEE for 30
min. Next, Jurkat T cells (40 
 
 
 
 10
 
6
 
 per group) were added at the
ratio of 5:1 and incubated for 30 min. Cells were pelleted,
washed once in cold PBS, and used for lipid raft isolation. Lipid
raft isolation was done as reported previously (8). Briefly, 40–80 
 
 
 
10
 
6
 
 T cells were lysed in buffer containing 0.5% Triton X-100,
25 mM MES, 150 mM NaCl, 1 mM Na
 
3
 
VO
 
4
 
, 2 mM EDTA, 1
mM PMSF, and 1 
 
 
 
g/ml aprotinin. Lysates were then homoge-
nized, mixed with equal volume of 85% wt/vol sucrose, and put
under a step gradient consisting of 35% wt/vol and 5% wt/vol
layers of sucrose in MBS (25 mM MES, 150 ml NaCl, pH 6.5)
supplemented with 1 mM Na
 
3
 
VO
 
4
 
 and 2 mM EDTA. Samples
were then ultracentrifuged for 16–18 h at 200,000 
 
g
 
, 4
 
 
 
C. 12 1-ml
fractions were taken starting at the top, with fraction 5 con-
taining the cloudy band indicative of rafts and fraction 12 taken as
the soluble fraction. Fraction aliquots were mixed with 4
 
 
 
 sam-
ple buffer (8% SDS, 8% 2-mercaptoethanol, 250 mM tris, 40%
glycerol, 2% bromophenol blue, dd-H
 
2
 
O) to a final dilution of
1
 
 
 
. Immunoprecipitation was done as described previously (34)
except that lipid raft fractions were first pelleted by adding equal
volume of MBS, centrifuging for 10 min at 14,000 rpm, 4
 
 
 
C on a
table top microcentrifuge, and resuspended in 1 ml lysis buffer.
Fractions were run on SDS-PAGE and immunoblotted as de-
scribed previously (34). Where indicated, samples were diluted
by 10 with 1
 
 
 
 sample buffer. Chemiluminescence signals were
scanned with a GS-700 Imaging densitometer and analyzed by
Multi Analyst software (Bio-Rad Laboratories). Mean OD was
measured for each band and corrected for dilution where applica-
ble. The percentage of total CTLA-4 within lipid rafts was deter-
mined using the conversion formula (mean OD rafts)/(mean OD
soluble 
 
 
 
 mean OD raft) 
 
 
 
 100%.
 
Cell Surface Biotinylation.
 
To biotinylate molecules on the
surface of Jurkat T cells, cells were washed twice with 1
 
  
 
PBS (1
ml) and rotated for 30 min in 0.5 mg/ml EZ-link Sulfo-NHS-
LC-biotin (Pierce Chemical Co.) in PBS, pH 8.0, at a cell con-
centration of 25 
 
 
 
 10
 
6
 
/ml. Samples were washed three times
with 1
 
  
 
PBS before raft isolation. In experiments looking at the
percentage of total CTLA-4 expressed on the cell surface, cell ly-
sates from biotinylated cells were immunoprecipitated with anti-
bodies against biotin or against CTLA-4, and these immunopre-
cipitates were subsequently blotted with CTLA-4. Additionally,
CTLA-4 immunoprecipitates of raft and soluble fractions from
biotinylated wild-type CTLA-4–transfected T cells in the pres-
ence or absence of doxycycline were prepared and immuno-
blotted with HRP-conjugated avidin (Bio-Rad Laboratories).
CTLA-4 signals or avidin signals in each group were analyzed by
densitometry using the Phoretix 1D advanced v5.1 software
(Nonlinear USA Inc.). In experiments looking at the effect of T
cell stimulation on CTLA-4 distribution, biotinylation was per-
formed under the same conditions, immediately after SEE and
APC stimulation using 200 
 
 
 
 10
 
6
 
 doxycycline-induced, wild-
type CTLA-4 transfected T cells, 60 
 
 
 
 10
 
6
 
 tailless CTLA-4 trans-
fected T cells, or GPI-anchored CTLA-4 T cell transfectants. All
biotinylation steps were done at room temperature to prevent bi-
otin precipitation.
 
Results
 
Wild-Type CTLA-4 Redistributes to the Immunological Syn-
apse upon Coligation with the TCR.
 
The main obstacle to
assess the membrane distribution of CTLA-4 has been the
low, transient level of CTLA-4 expression on the surface of
primary T lymphocytes. Of the very low levels of CTLA-4
produced, only 5% reaches the membrane and is rapidly in-
ternalized (21). To circumvent this problem, we used Jur-
kat T cells which do not express endogenous CTLA-4, and
stably transfected with a doxycycline-inducible expression
vector for wild-type CTLA-4 or mutants of CTLA-4. This
system provides a powerful model to address CTLA-4
structure-function analysis as described previously (20, 24).
The three transfectants for the studies reported here include
wild-type CTLA-4, CTLA-4 without the cytoplasmic tail
(so called tailless CTLA-4), and a newly generated chimer-
ical version of CTLA-4 consisting of its extracellular do-
main fused to the CD58 GPI-anchor.
The expression of CTLA-4, CD3, CD28, and CD45 in
the absence or presence of doxycycline is shown in Fig. 1
A for representative stably transfected T cell clones. With-
out doxycycline, wild-type CTLA-4 transfected cells ex-
pressed barely detectable levels of the recombinant protein.
In contrast, tailless CTLA-4 and GPI-anchored CTLA-4
Jurkat T cell transfectants had a detectable degree of “leaki-
ness”, which was amplified by the inability of these CTLA-4
molecules to be endocytosed (35, 36). Upon induction
with doxycycline, a significant increase in surface expres-
sion of CTLA-4 was detected in all the transfectants (Fig. 1
A). As Jurkat T cells do not express endogenous CTLA-4,
all of the CTLA-4 expression comes from the transfected
cDNA. Doxycycline did not affect the surface levels of
CD3 or CD28 (Fig. 1 A). As expected, the percentage of
total CTLA-4 expressed on the cell surface varied for each
one of the transfectants (20–25% for wild-type CTLA-4,
close to 100% for the tailless CTLA, and around 80% for
the GPI-anchored CTLA-4) even though the total levels of
CTLA-4 in the three T cell transfectants after doxycycline
induction were comparable (24; Fig. 1 B). Appropriate iso-
type-matched immunoprecipitation controls showed no 
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reactivity. The higher levels of the tailless and GPI-anchored
mutants are due to inability of these forms to be internal-
ized once they reach the cell surface because of the lack of
tyrosine-centered, activating protein 2 (AP-2)–binding sites
(35, 36).
Using these CTLA-4 transfectants, we then examined
the distribution of surface CTLA-4 in relation to the IS by
confocal microscopy (Fig. 2). T cell transfectants were
stimulated with the superantigen SEE and an APC express-
ing high levels of B7 and MHC class II molecules. In the
absence of SEE stimulation, both CD3 and CTLA-4 were
homogeneously distributed on the surface of the T cells
(Fig. 2 A). As the T cells were not permeabilized, no intra-
cellular CTLA-4 was detectable. Upon SEE stimulation,
CD3 migrated to the interface between the T cell and APC
(Fig. 2 A). LFA-1 and PKC
 
 
 
 also migrated to this area (data
not shown), indicating that this interface is a putative IS.
More importantly, after doxycycline induction, wild-type
CTLA-4 migrated to this interface between T cell and
APC and colocalized with CD3 upon stimulation with
SEE and APC, conditions that correlate with inhibition of
IL-2 production (see below). In addition, CD43 was ex-
cluded of the CTLA-4 cluster at the center of the T cell–
APC interface (data not shown), supporting the idea that
the CTLA-4 cluster is in the immunological synapse. Simi-
lar to the wild-type CTLA-4, GPI-anchored CTLA-4 was
evenly distributed on the membrane in resting cells and mi-
grated to the IS upon SEE stimulation, where it colocalized
with CD3. Tailless CTLA-4 migrated to the IS although
the frequency of colocalization with CD3 was lower than
that seen with wild-type CTLA-4 as well as with GPI-
anchored CTLA-4 as shown by quantification of CD3-
CTLA-4 cocapping under conditions of doxycycline in-
duction and coligation induced by SEE and APC (Fig. 2
A). For the GPI-anchored CTLA-4 transfectants and the
tailless CTLA-4 transfectants, we show these experiments
Figure 1. Inducible surface expression of wild-type or mutant CTLA-4 on Jurkat T cell clones. (A) Jur-
kat T cells stably transfected for CTLA-4 on a doxycycline inducible enhancer-promoter. T cells were cul-
tured with 5  g/ml of doxycycline overnight (solid line) or without it (dotted line), and were analyzed by
FACS® for surface expression of CTLA-4, CD3, CD28, and CD45. Shown are representative T cell clones
stably transfected with the wild-type CTLA-4 gene, a version of CTLA-4 that lacks the cytoplasmic tail
(tailless CTLA-4), and a chimerical molecule consisting of the extracellular domain of CTLA-4 fused to the
GPI-anchor of CD58 (GPI-anchored CTLA-4). The staining control is shown in gray. Note that the very
high expression of GPI-anchored and tailless CTLA-4 after doxycycline induction is above 104. (B) Per-
centage of wild-type (WT), tailless (TL), or GPI-anchored CTLA-4 that is expressed on the cell surface. T
cell transfectants were biotinylated and underwent immunoprecipitation for biotinylated, i.e., surface, mol-
ecules (S), for total CTLA-4 (T), or for an isotype-matched irrelevant antibody control (C), using antibod-
ies covalently cross-linked to beads. These immunoprecipitates were subsequently blotted for CTLA-4.
Bands were analyzed by densitometry and plotted as percentage of total CTLA-4 that was biotinylated. 
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Figure 2. CTLA-4 colocalizes in
the IS with CD3 and GM1. Wild-
type CTLA-4 transfected Jurkat T
cells were induced with doxycy-
cline or noninduced and incubated
on poly-l-lysine coated confocal
dishes with APC plus 100 ng/ml
SEE where indicated. Similarly,
tailless and GPI-anchored CTLA-4
in the absence of doxycycline (as
these cells express significant
amounts of CTLA-4 without it)
were used. The samples were put
on ice to prevent receptor internal-
ization and immunostained for (A)
CD3 (green) and CTLA-4 (red) or
(B) GM1 (green) and CTLA-4
(red). The samples were then ana-
lyzed by confocal microscopy. Co-
capping of CD3 and CTLA-4 was
scored when both colocalized at
the interface between T cell and
APC and the cluster stained  50%
of the cell surface. At least 100
doublets per group were counted
and scored and results are shown at
the bottom right of Fig. 2 A. APCs
were identified based on their mor-
phology and lack of staining for
CTLA-4 and CD3. Light field pic-
tures were taken simultaneously
and merged with the color fields.
Yellow indicates overlay of red and
green signals. 
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in the absence of doxycycline induction, as under these
conditions, the level of CTLA-4 expression on the surface
is more comparable.
Next, we examined the localization of surface CTLA-4
in relation to lipid rafts. The ganglioside GM1, enriched in
lipid rafts, was used as a marker for these microdomains. It
had been previously shown that GM1 migrates to the point
of TCR engagement (7). Consistent with these reports, we
found that GM1 became enriched in the IS upon stimula-
tion with SEE. We found that both wild-type and GPI-
anchored CTLA-4 colocalized with GM1 (Fig. 2 B).
Again, in the tailless CTLA-4–transfected T cells, GM1 did
not migrate to the synapse as frequently (Fig. 2 B). These
results indicate that under conditions of TCR-CTLA-4
coligation, CTLA-4 relocates to the IS.
 
Most CTLA-4 Within Lipid Rafts Is on the T Cell Sur-
face.
 
The colocalization of CTLA-4 and GM1 observed
by confocal microscopy is only suggestive that CTLA-4
might be found in lipid rafts. To confirm this prediction,
we looked for the presence of CTLA-4 within lipid rafts
using an established subcellular fractionation protocol (8).
Lipid rafts are defined as detergent insoluble, low density
compartments which are enriched for GM1, src-kinases
such as lck, and LAT, and exclude CD45 and the cytoso-
lic kinases ERK-1/-2 both found in high density soluble
fractions (8, 9) (P. Darlington and J. Madrenas, personal obser-
vation). When lipid rafts from resting, wild-type CTLA-4–
expressing T cell transfectants were analyzed by gel electro-
phoresis under reducing conditions, 
 
 
 
5–10% of the total
amount of CTLA-4 was in lipid rafts while most CTLA-4
was within the soluble fraction (Fig. 3 A). In contrast, only
2% of the total amount of tailless CTLA-4 was found in
rafts. In terms of total levels, there was 3.6 times more
wild-type CTLA-4 than tailless CTLA-4 in lipid rafts as
determined by densitometry (Fig. 3 B). The discrepancy
between the amount of wild-type versus tailless CTLA-4 in
the rafts is striking considering that the surface expression
of tailless CTLA-4 is more than 100 times higher than that
of wild-type CTLA-4 (Fig. 1). The quality of the lipid raft
fractionation procedure was documented by the selective
compartmentalization of GM1 within lipid rafts and of
ERK-1/-2 and CD45 within the soluble fractions (Fig. 3
C). Thus, confocal microscopy and subcellular fraction-
ation demonstrate that CTLA-4 can be seen within lipid
rafts in a cytoplasmic tail-dependent manner. The finding
that CD45, a transmembrane molecule highly expressed on
T cells (37), was found mostly in the soluble fraction indi-
cates that high levels of expression of a molecule does not
determine its nonspecific localization within lipid rafts. As
expected based on the raft localization of other GPI-
anchored molecules, the GPI-anchored CTLA-4 was pre-
dominantly in the lipid rafts. The magnitude of raft-associ-
ation of GPI-anchored CTLA-4 rules out the possibility
that exclusion from rafts of tailless CTLA-4 is due to a lim-
iting capacity of these microdomains to accommodate
more molecules.
As the functional pool of CTLA-4 is primarily that on
the cell surface, we determined whether or not the CTLA-4
found within lipid rafts was from the surface. To track
surface-CTLA-4, uninduced and doxycycline-induced Jur-
kat T cell transfectants were biotinylated. Next, biotin-
ylated (surface) molecules from lipid raft and soluble frac-
Figure 3. Wild-type CTLA-4 is within lipid rafts in a tail-dependent
manner. Lipid raft (R) and detergent-soluble (S) fractions were isolated
from resting Jurkat T cells transfected with wild-type CTLA-4, tailless
CTLA-4, or GPI-anchored CTLA-4 molecules induced with doxycy-
cline or left noninduced. (A) Selected fractions were run on SDS PAGE
and Western blotted for CTLA-4. Where indicated by an asterisk (*) the
samples were diluted 10-fold with 1  sample buffer before loading in or-
der to assess nonsaturated signals for CTLA-4 in these samples. CTLA-4
is detected as a broad band attributed to differential glycosylation and in-
termediate GPI-anchored molecules. (B) Band intensities from the film in
panel A were quantified by densitometry and used to calculate the per-
centage of total CTLA-4 within lipid rafts (see Materials and Methods).
(C) The fractions used in the experiment (A) were immunoblotted for
ERK-1/-2, CD45, and GM1 to control for quality of the separation.
ERK-1/-2 and CD45 were found in the soluble fraction while GM1 par-
titioned within lipid rafts. 
1343
 
Darlington et al.
 
tions were immunoprecipitated, and blotted for CTLA-4.
In these experiments, we found that most wild-type
CTLA-4 on the cell surface was located in lipid raft frac-
tions while the majority of biotinylated, GPI-anchored
CTLA-4 was within lipid rafts and all the biotinylated tail-
less CTLA-4 was found in the soluble fraction (Fig. 4 A).
This approach may have underestimated the amount of
surface CTLA-4 in the soluble fraction due to saturation of
the anti-biotin immunoprecipitating antibody with other
biotinylated molecules. To assess this possibility, we per-
formed avidin blotting of CTLA-4 immunoprecipitates of
subcellular fractions. This blotting strategy showed that
there was biotinylated CTLA-4 within the soluble fraction.
However, when correcting the avidin signals for the
CTLA-4 signal in each fraction, we found that the ratio of
biotinylated (i.e., surface) CTLA-4 over total CTLA-4 in
lipid rafts was higher (82%) than in the soluble fraction
(24%; Fig. 4 B). Therefore, we can conclude that most
CTLA-4 partitioning within lipid rafts is located on the
cell surface.
To assess the biological relevance of the raft-associated
pool of wild-type CTLA-4, we determined the presence of
CTLA-4 dimers in the raft and soluble fractions, as these
are the potentially functional forms of this molecule. A 50-
kD band with CTLA-4 immunoreactivity was detectable
 
when CTLA-4 immunoprecipitates from rafts were immu-
noblotted in nonreducing conditions (Fig. 5). This finding
suggests that the CTLA-4 molecules found in lipid rafts are
potentially functional.
 
The Amount of CTLA-4 Within Cell Surface Lipid Rafts In-
creases Under Conditions of CTLA-4–mediated Inhibition of T
Cell Activation.
 
The current model of IS formation pro-
poses that lipid rafts cluster in the IS after T cell stimulation,
and provide the permissive environment to sustain early
TCR-dependent signaling (6). Thus, we examined the ef-
fect of TCR-mediated T cell activation on the distribution
of CTLA-4 in lipid rafts. After stimulation of wild-type
CTLA-4–expressing T cells with SEE plus APC, we de-
tected an increase in the total levels of CTLA-4 within the
lipid rafts (Fig. 6 A). When the cells were biotinylated after
stimulation we found that the biotinylated CTLA-4 in-
creased dramatically in lipid raft fractions (Fig. 6 B). No sig-
nificant change in the levels of CTLA-4 was observed in the
soluble fraction upon SEE plus APC stimulation (Fig. 6, A
and B). Under these conditions, there was significant inhibi-
tion of IL-2 production in response to SEE (Fig. 6 C). This
inhibition was significantly released when engagement of
CTLA-4 was blocked with soluble single chain anti-
body against CTLA-4 (
 
P
 
 
 
  
 
0.05 by analysis of variance
[ANOVA]; Fig. 6 D). Consistent with what we have re-
Figure 4. Most lipid raft-associated CTLA-4 is on the cell
surface. (A) Wild-type, tailless, and GPI-anchored CTLA-4 T
cell transfectants were induced with doxycycline or nonin-
duced, surface biotinylated, and separated into raft and soluble
fractions. These fractions were immunoprecipitated for
CTLA-4 and for biotin, and Western blotted for CTLA-4.
The light chain of the immunoprecipitating antibodies is indi-
cated. The GPI-anchored and tailless CTLA-4 samples were
diluted 10-fold before loading on the gel, based on total ex-
pression of CTLA-4 to prevent signal saturation. In addition,
three times fewer cells were used for tailless CTLA-4 and GPI-
anchored CTLA-4 transfectants compared with wild-type
CTLA-4 transfectants. Antibody-coated beads rotated in lysis
buffer are shown as negative control. Representative isotype-
matched control antibody immunoprecipitations (Ctrl.) are shown. (B) CTLA-4 immunoprecipitates of lipid raft and soluble fractions from noninduced
and induced, biotinylated wild-type CTLA-4 transfected T cells were sequentially immunoblotted with avidin and with anti–CTLA-4 antibody. Signals
were quantified and the ratio of biotinylated CTLA-4 (sCTLA-4) over total CTLA-4 (tCTLA-4) for each fraction plotted in percentage. 
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ported previously (20, 24), expression of surface CTLA-4
upon SEE stimulation for 30 min was slightly increased (Fig.
6 E) but did not affect the total levels of LAT, GM1, or lck
within lipid rafts (data not shown). These results demon-
strate that surface CTLA-4 is preferentially located within
lipid rafts under conditions of inhibition of T cell activation.
 
Location of CTLA-4 Within Lipid Rafts Is Required But
Not Sufficient for CTLA-4–mediated Negative Signaling.
 
Next, we determined whether or not the ability of CTLA-4
to negatively signal correlated with its membrane com-
partmentalization. One could argue that localization of
CTLA-4 in lipid rafts may be sufficient to interfere with
TCR-mediated signaling upon coligation by causing phys-
 
ical disruption of the IS. To test this hypothesis we stimu-
lated the different T cell transfectants with immobilized
monoclonal antibodies against CD3 or against CD3 and
CTLA-4 on beads in the presence of excess costimulation
provided by soluble anti-CD28 mAbs. Our group has pre-
viously reported that coligation of TCR and wild-type
CTLA-4 results in inhibition of ERK1/ERK2 phosphory-
lation and of IL-2 production, while tailless CTLA-4 does
not cause such inhibition by negative signaling (20, 24). As
expected, we confirmed that coligation of CD3 and wild-
type-CTLA-4 caused significant inhibition of IL-2 pro-
duction (Fig. 7 A). Blockade of CTLA-4 coligation pre-
vented the inhibition of IL-2 production under these
conditions, suggesting that CTLA-4 is responsible for this
effect (Fig. 7 B). However, the GPI-anchored-CTLA-4,
like we have previously reported for tailless CTLA-4 (20),
failed to inhibit T cell activation by negative signaling
upon coligation with CD3 and CD28 (Fig. 7 A), despite its
almost exclusive localization within lipid rafts. Taken to-
gether these results demonstrate that while raft localization
may be necessary for inhibition to occur, it is not sufficient
to mediate negative signaling.
 
Discussion
 
In this study, we show for the first time the membrane
compartmentalization of CTLA-4 in T lymphocytes under
conditions of CTLA-4–mediated inhibition of T cell acti-
vation. Our data demonstrate that a significant fraction of
surface CTLA-4 compartmentalizes in the lipid rafts and
accumulates at the IS with CD3 and GM1. Such compart-
mentalization is determined by the cytoplasmic tail of
CTLA-4. From a functional point of view, coligation of
Figure 5. CTLA-4 in lipid rafts is homodimeric. Lipid rafts and soluble
fractions from doxycycline induced and noninduced wild-type CTLA-4
T cell transfectants were immunoprecipitated for CTLA-4 or an isotype-
matched irrelevant control (Ctrl.). Immunoprecipitates were analyzed by
SDS PAGE in nonreducing conditions (NR) and reducing (R) condi-
tions, and Western blotted for CTLA-4.
Figure 6. The levels of CTLA-4 within lipid rafts increase under con-
ditions of T cell inhibition. (A) Doxycycline-induced, wild-type T cell
transfectants were incubated with APC plus or minus 100 ng/ml SEE for
30 min, and separated into lipid raft and soluble fractions. These fractions
were immunoprecipitated for CTLA-4 and Western blotted for CTLA-4.
The CTLA-4 immunoprecipitations from the soluble fractions were di-
luted 10-fold to prevent signal saturation. (B) Wild-type T cell transfec-
tants were stimulated as in panel A and then surface biotinylated before
raft isolation. Biotinylated proteins were immunoprecipitated from the
fractions and Western blotted for CTLA-4. The soluble fractions were
not diluted before loading. (C) Wild-type T cell transfectants were stimulated with SEE and APC for 48 h in the absence ( ) or presence ( ) of doxy-
cycline to induce CTLA-4 expression. The amount of IL-2 in the supernatant was determined by ELISA. (D) Doxycycline induced Jurkat T cells were
preincubated with or without anti–human CTLA-4 ScFv F ab blocking single chain fragment for 30 min. Then, APCs and SEE were added to the cells
and IL-2 production was measured after 48 h. Results were statistically significant as analyzed by one-way ANOVA (P   0.05). (E) Non-induced and
doxycycline-induced wild-type–transfected Jurkat T cells were stimulated with APC and SEE for 30 min and CTLA-4 expression on the cell surface was
analyzed by flow cytometry. (Non-induced, nonstimulated, control antibody: light dotted line; noninduced, nonstimulated, CTLA-4 stained: thin line;
doxycycline-induced, nonstimulated cells: dashed line; doxycycline-induced, stimulated cells: thick line. 
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CTLA-4 with the TCR is associated with an increase in
the levels of CTLA-4 within lipid rafts. However, ligation
of CTLA-4 within lipid rafts is not sufficient to inactivate
T cells by CTLA-4-mediated signaling.
Compartmentalization of CTLA-4 on the T cell surface
has been difficult to examine given the low level of CTLA-4
expression in primary, activated T cells. This forced us to
generate a panel of Jurkat T cells expressing high levels of
wild-type CTLA-4 upon doxycycline induction. In this
way, we achieved sufficient surface CTLA-4 for biochemi-
cal, functional, and microscopy studies. More importantly,
as Jurkat T cells do not express endogenous CTLA-4, these
cells are ideal to assess the structural requirements for
CTLA-4 compartmentalization using mutant molecules
such as the ones reported here (tailless CTLA-4, GPI-
anchored CTLA-4). An additional advantage of the system
used in these studies is that we were able to examine the
surface compartmentalization under conditions of APC-
driven T cell stimulation, making the stimulation condi-
tions more physiologically relevant than previously used
monoclonal antibody stimulation.
The recently reported crystal structures of CTLA-4 have
 
led to the proposal that, upon ligation by B7 homodimers,
CTLA-4 could form a lattice-like structure whose inter-
membrane dimension (100–140 Å) might be accommo-
dated within the IS (29–32). Our finding of CTLA-4 in
the IS is consistent with this model. Furthermore, our data
indicate that this lattice does not grossly disrupt the mor-
phology of the IS. This is particularly significant for the
TCR complex, as one could claim that the negative func-
tion of CTLA-4 may be through interference with TCR
oligomerization at the IS. Our findings stress the concept
that CTLA-4 and CD3 have to be physically coligated for
negative signaling to occur, consistent with the data indi-
cating that such coligation is only functional when in cis,
i.e., both ligands on the same surface (20, 24, 33). Future
studies will be required to determine the effect that
CTLA-4 may have on the fine stoichiometry and organiza-
tion of the IS.
We have also analyzed the compartmentalization of
CTLA-4 with respect to lipid rafts. The majority of
CTLA-4 was outside of lipid rafts. However, a significant
fraction of total CTLA-4 was within lipid rafts. The cyto-
plasmic tail of CTLA-4 was required for its efficient local-
ization within lipid rafts, a novel finding indicating that the
cytoplasmic region and not the transmembrane region
alone (which is present in the tailless CTLA-4) is critical for
raft association. The exact residues within the tail responsi-
ble for the lipid raft localization are unknown. As expected
from previous reports of GPI-anchored molecules being
enriched in lipid rafts (38, 39), a GPI-anchored version of
CTLA-4 was found mostly in these microdomains.
The physiological relevance of lipid raft-associated
CTLA-4 is currently unknown. As CTLA-4 in lipid rafts
can be found as homodimers and clusters to the IS, it is
plausible to assume that the pool within lipid rafts is func-
tional. More importantly, the observation that the content
of CTLA-4 within lipid rafts increased under conditions
of CTLA-4–mediated inhibition further supports this
claim. Such an increase may be explained by retention of
CTLA-4 on the cell surface upon TCR ligation or alter-
natively, by a net increase of CTLA-4 migration into lipid
rafts.
The compartmentalization of CTLA-4 within lipid rafts
has implications for the search of CTLA-4 targets and/or
regulators since one would expect that such molecules are
located in these microdomains. Our data are compatible
with the model proposing that TCR-
 
 
 
 is the target of
CTLA-4 as the phosphorylated form of this chain has been
found in lipid rafts (26). However, it should be noted that
in the T cell system described in this report, we have not
been able to detect CTLA-4 associated with TCR-
 
 
 
 or
SHP-2 (unpublished data). We and others favor an effect of
CTLA-4 on ERK activation and JNK signaling (23, 24,
28), which is also consistent with the lipid raft compart-
mentalization of CTLA-4, as lipid rafts are enriched in
LAT and ras (8, 9). Similar considerations apply to regula-
tors of CTLA-4 function such as the regulatory subunit of
the serine/threonine phosphatase PP2A (39a). Therefore,
the presence of the regulatory machinery of CTLA-4 func-
Figure 7. Wild-type CTLA-4, but not GPI-anchored CTLA-4, inhib-
its IL-2 production upon coligation with the TCR. (A) Wild-type
CTLA-4 and GPI-anchored CTLA-4 were incubated with or without
100 ng/ml doxycycline, and incubated with anti-CD3 or anti-CD3 plus
anti–CTLA-4 coated beads and soluble anti-CD28 for 48 h. IL-2 in the
supernatant was determined by ELISA. The percentage change in IL-2
production in response to anti-CD3 plus anti-CTLA-4 is shown as a bar
graph. The response to anti-CD3 beads was taken as 100% for each trans-
fectant. (B) Doxycycline-induced Jurkat T cells were preincubated with
or without blocking anti-CTLA-4 ScFv F ab. After 30 min, beads coated
with the indicated antibodies were added to the cells in the presence of
soluble anti-CD28 antibodies. IL-2 production was measured after 48 h.
Result were statistically significant as analyzed by one-way ANOVA
(P   0.05). 
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tion and of the potential targets of this molecule within
lipid rafts argues that the lipid raft-associated fraction of
CTLA-4 is biologically important.
As most of the lipid raft-associated CTLA-4 is on the cell
surface, and this pool increases after coligation with the
TCR, we propose that raft localization is necessary for
CTLA-4–mediated negative signaling. In support of this
claim is the data that tailless CTLA-4 that is mostly outside
lipid rafts failed to inhibit T cell activation by negative sig-
naling. However, raft localization of CTLA-4 is not suffi-
cient for CTLA-4–mediated negative signaling, as the GPI-
anchored CTLA-4 that is almost exclusively in lipid rafts
and migrates to the IS did not inhibit T cell activation. We
cannot exclude fine molecular differences in the lattice
formed by the GPI-anchored CTLA-4 compared with that
formed by the wild-type CTLA-4. However, the sugges-
tion of lattice formation was made from crystals in which
only the extracellular domain of CTLA-4 was used, and
thus it is plausible to assume that lattice formation may be
primarily determined by the extracellular portion of
CTLA-4.
The results of this study can be incorporated into a
broader model of CTLA-4 trafficking. The majority of
CTLA-4 in a resting, previously activated T cell would
be primarily in intracellular, detergent soluble compart-
ments where it is constantly being shuttled to the sur-
face, where it compartmentalizes in lipid rafts. This pool
is reinternalized via an AP-2–dependent process (21,
36). The localization within lipid rafts may facilitate that
process, as it is well established that lipid rafts are in-
volved in internalization (40). Upon TCR ligation,
CTLA-4 is tyrosine phosphorylated in a lck and ZAP-
70–dependent manner (24). This phosphorylation event
prevents AP-2–dependent internalization, and leads to
retention of CTLA-4 on the cell surface. In addition,
polarization of the intracellular stores of CTLA-4 to-
ward the APC would facilitate its release into the IS
(41). The raft-associated CTLA-4 would then cluster in
the IS, where it could potentially mediate the formation
of extended lattice networks of B7 and CTLA-4 (29).
Further studies on the specific contribution of the cyto-
plasmic tail and lipid raft compartmentalization to
CTLA-4 relocation into the IS should help us to identify
the fine molecular arrangement within this highly orga-
nized interface.
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